Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study

CONCLUSIONS: In real-world patients with mCSPC, significantly more patients achieved PSA90 with apalutamide than with abiraterone acetate, and this response was achieved earlier with apalutamide.PMID:37080833 | DOI:10.1016/j.urolonc.2023.03.013

Source: Urologic Oncology - April 20, 2023 Category: Urology & Nephrology Authors: Benjamin Lowentritt Dominic Pilon Dexter Waters Carmine Rossi Erik Muser Siyana Kurteva Aditi Shah Ibrahim Khilfeh Shawn Du Lorie Ellis Patrick Lefebvre Gordon Brown Source Type: research